Effectiveness and Optimal Duration of Adjunctive Rifampin Treatment in the Management of Prosthetic Joint Infections After Debridement, Antibiotics, and Implant Retention.

Suzuki H, Goto M, Nair R, Livorsi DJ, Sekar P, Ohl ME, Diekema DJ, Perencevich EN, Alexander B, Jones MP, McDaniel JS, Schweizer ML. Effectiveness and Optimal Duration of Adjunctive Rifampin Treatment in the Management of Prosthetic Joint Infections After Debridement, Antibiotics, and Implant Retention. Open forum infectious diseases. 2022 Sep 1; 9(9):ofac473.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: Rifampin is recommended as adjunctive therapy for patients with a prosthetic joint infection (PJI) managed with debridement, antibiotics, and implant retention (DAIR), with no solid consensus on the optimal duration of therapy. Our study assessed the effectiveness and optimal duration of rifampin for PJI using Veterans Health Administration (VHA) data. METHODS: We conducted a retrospective cohort study of patients with PJI managed with DAIR between 2003 and 2019 in VHA hospitals. Patients who died within 14 days after DAIR were excluded. The primary outcome was a time to microbiological recurrence from 15 days up to 2 years after DAIR. Rifampin use was analyzed as a time-varying exposure, and time-dependent hazard ratios (HRs) for recurrence were calculated according to the duration of rifampin treatment. RESULTS: Among 4624 patients, 842 (18.2%) received at least 1 dose of rifampin; 1785 (38.6%) experienced recurrence within 2 years. Rifampin treatment was associated with significantly lower HRs for recurrence during the first 90 days of treatment (HR, 0.60 [95% confidence interval {CI}, .45-.79]) and between days 91 and 180 (HR, 0.16 [95% CI, .04-.66]) but no statistically significant protective effect was observed with longer than 180 days (HR, 0.57 [95% CI, .18-1.81]). The benefit of rifampin was observed for subgroups including knee PJI, methicillin-susceptible or -resistant infection, and early or late PJI. CONCLUSIONS: This study supports current guidelines that recommend adjunctive rifampin use for up to 6 months among patients with PJI treated with DAIR.